The New England Journal of Medicine has retracted what Amgen described as pivotal data for its autoimmune therapy Tavneos, following author requests for removal. The step adds another regulatory and clinical-friction hurdle for a treatment that has faced scrutiny and setbacks. While specific trial details of the retracted material were not included in the announcement, the journal’s action signals a reputational and evidence-quality challenge that can affect how regulators and clinicians interpret the drug’s benefit-risk profile. For Amgen, the retraction is likely to compound downstream execution issues, particularly for ongoing labeling, payer conversations, and any future attempts to strengthen the evidentiary record for Tavneos. For the broader industry, it underscores how quickly publication-level changes can reverberate across clinical development plans.